| Thrive Wellness And Rehab, P.l.l.c | |
|
103 Livingston Loop, Ste B-1, Santa Teresa, NM 88008-9747 | |
| (575) 587-7061 | |
| (915) 493-8264 |
| Full Name | Thrive Wellness And Rehab, P.l.l.c |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 103 Livingston Loop, Santa Teresa, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649528951 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Daniel D Gonzalez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780628271 PECOS PAC ID: 9830095843 Enrollment ID: I20121011000736 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Hector E Rodriguez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679978225 PECOS PAC ID: 2466776059 Enrollment ID: I20150202000213 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Joaquin F Santillan |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003985565 PECOS PAC ID: 6507815156 Enrollment ID: I20170118001602 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Marcela Bagues |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740769215 PECOS PAC ID: 6608127584 Enrollment ID: I20180918000277 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Mayra C Navarrete |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659640993 PECOS PAC ID: 5698101913 Enrollment ID: I20200930003191 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Victoria M Nunez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1811438674 PECOS PAC ID: 1850784687 Enrollment ID: I20220131001790 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Provider Name | Abigail H Delgado |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1689305252 PECOS PAC ID: 0042694184 Enrollment ID: I20220908002262 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thrive Wellness And Rehab, P.l.l.c 103 Livingston Loop, Ste B-1, Santa Teresa, NM 88008-9747 Ph: (575) 587-7061 | Thrive Wellness And Rehab, P.l.l.c 103 Livingston Loop, Ste B-1, Santa Teresa, NM 88008-9747 Ph: (575) 587-7061 |
News Archive
In recognition of 10 years of publication Future Cardiology has launched a special issue focused on recent advances and emerging challenges in specific areas of cardiology.
The private sector company Circle holds on to the first £2m of any annual surplus it achieves at Hinchingbrooke hospital in Cambridgeshire. They will also get a proportion of any income surplus above that level with the rest going towards paying off the hospital's £40m debt. This means that Circle would need to generate a £70m surplus from the hospital - which has a £100m turnover - over a decade to bring it out of the red. Over the past 10 years, the failing hospital - which was facing closure before the deal was made - has never recorded a surplus above £600,000.
BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante's receipt of Orphan Drug designation from the FDA's Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.
Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France's innovation agency, Oseo Innovation, in 2008.
Aging-US published "Comprehensive analysis of the competing endogenous circRNA-lncRNA-miRNA-mRNA network and identification of a novel potential biomarker for hepatocellular carcinoma" which reported that there is still a lack of comprehensive analysis of the circular RNA -long non-coding RNA -miRNA-mRNA ceRNA network in hepatocellular carcinoma.
› Verified 4 days ago
Joaquin F Santillan, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 103 Livingston Loop, Suite B1, Santa Teresa, NM 88008 Phone: 575-587-7061 Fax: 915-493-8264 | |
Function And Form Physical Therapy Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 5312 Rio Bravo Dr Ste 7, Santa Teresa, NM 88008 Phone: 575-201-3764 | |
Polly Curtis, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4950 Mcnutt Rd, Santa Teresa, NM 88008 Phone: 575-882-6200 | |
Ms. Laura G. Marusich, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1300 Country Club Rd, Suite C, Santa Teresa, NM 88008 Phone: 575-589-0303 Fax: 575-589-4080 | |
Abigail H Delgado, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 103 Livingston Loop Ste B1, Santa Teresa, NM 88008 Phone: 575-587-7061 Fax: 915-493-8264 | |
Marcela Bagues, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 103 Livingston Loop Ste B1, Santa Teresa, NM 88008 Phone: 575-587-7061 Fax: 915-493-8264 |